A Tumor Profile in Edwards Syndrome (Trisomy 18)

Daniel Satgé, Motoi Nishi, Nicolas Sirvent and Michel Vekemans
Additional contact information
Daniel Satgé: Laboratoire de pathologie - CH Tulle
Motoi Nishi: Department of Fundamental Health Sciences - Health Sciences University of Hokkaido
Nicolas Sirvent: Service de Pédiatrie, Unité d'Oncologie et Hématologie Pédiatrique - CHU Nice - Centre Hospitalier Universitaire de Nice
Michel Vekemans: IMAGINE - U1163 - Imagine - Institut des maladies génétiques - UPD5 - Université Paris Descartes - Paris 5 - INSERM - Institut National de la Santé et de la Recherche Médicale, Service de Génétique Médicale [CHU Necker] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)

Post-Print from HAL

Abstract: Constitutional trisomy 18 causes Edwards syndrome, which is ă characterized by intellectual disability and a particular set of ă malformations. Although this condition carries high mortality during ă prenatal and early postnatal life, some of the rare infants who survive ă the first months develop benign and malignant tumors. To determine the ă tumor profile associated with Edwards syndrome, we performed a ă systematic review of the literature. This review reveals a tumor profile ă differing from those of Down (trisomy 21) and Patau (trisomy 13) ă syndromes. The literature covers 45 malignancies: 29 were liver cancers, ă mainly hepatoblastomas found in Japanese females; 13 were kidney tumors, ă predominantly nephroblastomas; 1 was neuroblastoma; 1 was a Hodgkin ă disease; and 1 was acute myeloid leukemia in an infant with both trisomy ă 18 and type 1 neurofibromatosis. No instances of the most frequent ă malignancies of early life-cerebral tumors, germ cell tumors, or ă leukemia-are reported in children with pure trisomy 18. Tumor occurrence ă does not appear to correlate with body weight, tissue growth, or cancer ă genes mapping to chromosome 18. Importantly, the most recent clinical ă histories report successful treatment; this raises ethical concerns ă about cancer treatment in infants with Edwards syndrome. In conclusion, ă knowledge of the Edwards' syndrome tumor profile will enable better ă clinical surveillance in at-risk organs (i.e., liver, kidney). This ă knowledge also provides clues to understanding oncogenesis, including ă the probably reduced frequency of some neoplasms in infants and children ă with this genetic condition. (C) 2016 Wiley Periodicals, Inc.

Keywords: Quality; of; Life (search for similar items in EconPapers)
Date: 2016-09
References: Add references at CitEc
Citations:

Published in American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2016, 172 (3, SI), pp.296-306. ⟨10.1002/ajmg.c.31511⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482627

DOI: 10.1002/ajmg.c.31511

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().